Maintenance erlotinib improves clinical outcomes of unresectable advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials

Experimental and Therapeutic Medicine

Volumn 4, Issue 5, 2012, Pages 849-858

  Zhang, Jian ^a   Zhang, Weiqing ^a   Huang, Shaohong ^a   Li, Hui ^a   Li, Yun ^a   Chen, Huiguo ^a   Wu, Weibing ^a   Zhou, Wei ^a   Wang, Cuiping ^a   Liao, Hongying ^a   Gu, Lijia ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Epidermal growth factor receptor; Erlotinib; Maintenance therapy; Meta analysis; Non small cell lung cancer

Indexed keywords

ERLOTINIB;

ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; HUMAN; INFECTION; KIDNEY FAILURE; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; META ANALYSIS; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

EID: 84866388178     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.690     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics. CA Cancer J Clin 58: 71-96, 2008.
2. Govindan R, Page N, Morgensztern D, et al: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24: 4539-4544, 2006.
3. Stinchcombe TE, Bogart J, Wigle DA and Govindan R: Annual review of advances in lung cancer clinical research: a report for the year 2009. J Thorac Oncol 5: 935-939, 2010.
4. Pfister DG, Johnson DH, Azzoli CG, et al: American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003. J Clin Oncol 22: 330-353, 2004.
5. Park JO, Kim SW, Ahn JS, et al: Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol 25: 5233-5239, 2007.
6. Socinski MA, Schell MJ, Peterman A, et al: Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small cell lung cancer. J Clin Oncol 20: 1335-1343, 2002.
7. von Plessen C, Bergman B, Andresen O, et al: Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small cell lung cancer. Br J Cancer 95: 966-973, 2006.
8. Ciuleanu T, Brodowicz T, Zielinski C, et al: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374: 1432-1440, 2009.
9. Fidias PM, Dakhil SR, Lyss AP, et al: Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer. J Clin Oncol 27: 591-598, 2009.
10. Belani CP, Barstis J, Perry MC, et al: Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 21: 2933-2939, 2003.
11. Pirker R, Pereira JR, Szczesna A, et al: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373: 1525-1531, 2009.
12. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small cell lung cancer. J Clin Oncol 26: 3543-3551, 2008.
13. Stinchcombe TE and Socinski MA: Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapy. J Thorac Oncol 4: 243-250, 2009.
14. Gridelli C, Maione P, Rossi A, et al: Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line? Oncologist 14: 137-147, 2009.
15. Butts C, Murray N, Maksymiuk A, et al: Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small cell lung cancer. J Clin Oncol 23: 6674-6681, 2005.
16. Cappuzzo F, Ciuleanu T, Stelmakh L, et al; SATURN investigators: Erlotinib as maintenance treatment in advanced non-small cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11: 521-529, 2010.
17. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 355: 2542-2550, 2006.
18. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al; National Cancer Institute of Canada Clinical Trials Group: Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353: 123-132, 2005.
19. Reck M, van Zandwijk N, Gridelli C, et al: Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV tarceva lung cancer survival treatment study. J Thorac Oncol 5: 1616-1622, 2010.
20. Gatzemeier U, Pluzanska A, Szczesna A, et al: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25: 1545-1552, 2007.
21. Herbst RS, Prager D, Hermann R, et al; TRIBUTE Investigator Group: TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer. J Clin Oncol 23: 5892-5899, 2005.
22. NHS Centre for Reviews and Dissemination: Undertaking systematic reviews of research on effectiveness: CRD's guidance for carrying out or commissioning reviews. CRD Report 4. 2nd edition. University of York, York, 2001.
23. Parmar MK, Torri V and Stewart L: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-2834, 1998.
24. Higgins JP, Thompson SG, Deeks JJ and Altman DG: Measuring inconsistency in meta-analyses. BMJ 327: 557-560, 2003.
25. Egger M, Davey Smith G, Schneider M and Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634, 1997.
26. Altman DG and Deeks JJ: Meta-analysis, Simpson's paradox, and the number needed to treat. BMC Med Res Methodol 2: 3, 2002.
27. McQuay HJ and Moore RA: Using numerical results from systematic reviews in clinical practice. Ann Intern Med 126: 712-720, 1997.
28. Smeeth L, Haines A and Ebrahim S: Numbers needed to treat derived from meta-analyses-sometimes informative, usually misleading. BMJ 318: 1548-1551, 1999.
29. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D and Stroup DF: Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 354: 1896-1900, 1999.
30. Mok TS, Wu YL, Yu CJ, et al: Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 27: 5080-5087, 2009.
31. Kabbinavar FF, Miller VA, Johnson BE, O'Connor PG, Soh C and ATLAS Investigators: Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol (meeting abstracts) 28: 7526, 2010.
32. Perol M, Chouaid C, Milleron BJ, et al: Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. J Clin Oncol (meeting abstracts) 28: 7507, 2010.
33. Davies AM, Ho C, Lara PN Jr, Mack P, Gumerlock PH and Gandara DR: Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small cell lung cancer. Clin Lung Cancer 7: 385-388, 2006.
34. Piperdi B, Ling YH and Perez-Soler R: Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small-cell lung cancer cell lines. J Thorac Oncol 2: 715-721, 2007.
35. Higgins B, Kolinsky K, Smith M, et al: Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs 15: 503-512, 2004.